INTERCEPT: Identifying and Managing Cancer Treatment Cardiotoxicities in Patients Undergoing Therapy: Novel Cardiovascular Toxicity - Immunotherapy, CAR-T and Other Therapy

July 13, 2021 to July 14, 2021

A curriculum designed to engage clinicians in an educational initiative aimed at improving the overall care for cancer patients at risk for cardiotoxicity associated with their treatment. This program is part 4 of 4 live webinars provided by expert clinical faculty.

Learning Objectives

Review recent data on novel targeted therapies and immunotherapies known to cause cardiotoxicity in cancer patients

Discuss the use of clinical tools, imaging, and other tests to evaluate patients at risk for cardiotoxicity before, during, and after cancer treatment

Employ multidisciplinary strategies to mitigate the risk for cardiotoxicity in cancer patients

Course summary
Available credit: 
  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
  • 1.00 MOC Part 2
Registration Opens: 
07/13/2021
Registration Expires: 
07/12/2022
Activity Starts: 
07/13/2021 - 4:00pm EDT
Activity Ends: 
07/14/2021 - 5:00pm EDT
Add to calendar: 
Rating: 
0

Available Credit

  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)™
  • 1.00 MOC Part 2
Please login or register to take this course.